The CXCL9 (chemokine), nerve growth factor β (β-NGF), and TNF-related apoptosis-inducing ligand (TRAIL) levels were independently associated with prognosis both at the time of PAH diagnosis and at the first follow-up after initiation of PAH therapy. The gene discussed is TNFSF10; the disease is pulmonary arterial hypertension.